Brodalumab

Jump to: navigation, search
Brodalumab
Black Box Warning
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Yashasvi Aryaputra[2], Anmol Pitliya, M.B.B.S. M.D.[3]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Black Box Warning

SUICIDAL IDEATION AND BEHAVIOR
See full prescribing information for complete Boxed Warning.
*Suicidal ideation and behavior, including completed suicides, have occurred in patients treated with brodalumab. Prior to prescribing brodalumab, weigh the potential risks and benefits in patients with a history of depression and/or suicidal ideation or behavior. Patients with new or worsening suicidal ideation and behavior should be referred to a mental health professional, as appropriate. Advise patients and caregivers to seek medical attention for manifestations of suicidal ideation or behavior, new onset or worsening depression, anxiety, or other mood changes.
  • Because of the observed suicidal behavior in subjects treated with brodalumab, brodalumab is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the brodalumab REMS Program.

Overview

Brodalumab is a human interleukin-17 receptor A (IL-17RA) antagonist that is FDA approved for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies. There is a Black Box Warning for this drug as shown here. Common adverse reactions include arthralgia, headache, fatigue, diarrhea, oropharyngeal pain, nausea, myalgia, injection site reactions, influenza, neutropenia, and tinea infections.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Indications:
  • Brodalumab is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies.
Dosage
  • The recommended brodalumab dose is 210 mg administered by subcutaneous injection at Weeks 0, 1, and 2 followed by 210 mg every 2 weeks.
  • If an adequate response has not been achieved after 12 to 16 weeks of treatment with brodalumab, consider discontinuing therapy. Continued treatment beyond 16 weeks in patients who have not achieved an adequate response is not likely to result in greater success.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding brodalumab Off-Label Guideline-Supported Use and Dosage (Adult) in the drug label.

Non–Guideline-Supported Use

There is limited information regarding brodalumab Off-Label Non-Guideline-Supported Use and Dosage (Adult) in the drug label.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

There is limited information regarding Brodalumab FDA-Labeled Indications and Dosage (Pediatric) in the drug label.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding brodalumab Off-Label Guideline-Supported Use and Dosage (Pediatric) in the drug label.

Non–Guideline-Supported Use

There is limited information regarding brodalumab Off-Label Non-Guideline-Supported Use and Dosage (Pediatric) in the drug label.

Contraindications

  • Brodalumab is contraindicated in patients with Crohn’s disease because brodalumab may cause worsening of disease.

Warnings

SUICIDAL IDEATION AND BEHAVIOR
See full prescribing information for complete Boxed Warning.
*Suicidal ideation and behavior, including completed suicides, have occurred in patients treated with brodalumab. Prior to prescribing brodalumab, weigh the potential risks and benefits in patients with a history of depression and/or suicidal ideation or behavior. Patients with new or worsening suicidal ideation and behavior should be referred to a mental health professional, as appropriate. Advise patients and caregivers to seek medical attention for manifestations of suicidal ideation or behavior, new onset or worsening depression, anxiety, or other mood changes.
  • Because of the observed suicidal behavior in subjects treated with brodalumab, brodalumab is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the brodalumab REMS Program.
Suicidal Ideation and Behavior
  • Suicidal ideation and behavior, including 4 completed suicides, occurred in subjects treated with brodalumab in the psoriasis clinical trials. There were no completed suicides in the 12-week placebo-controlled portion of the trials. Brodalumab users with a history of suicidality or depression had an increased incidence of suicidal ideation and behavior as compared to users without such a history. A causal association between treatment with brodalumab and increased risk of suicidal ideation and behavior has not been established.
  • Prescribers should weigh the potential risks and benefits before using brodalumab in patients with a history of depression or suicidality. Patients with new or worsening symptoms of depression or suicidality should be referred to a mental health professional, as appropriate. Advise patients and caregivers to seek medical attention for manifestations of suicidal ideation and behavior, new onset or worsening depression, anxiety, or other mood changes. Prescribers should also re-evaluate the risks and benefits of continuing treatment with brodalumab if such events occur.
  • Because of the observed suicidal ideation and behavior in subjects treated with brodalumab, if an adequate response to brodalumab has not been achieved within 12 to 16 weeks, consider discontinuing therapy.
  • Brodalumab is available only through a restricted program under a REMS.
Brodalumab REMS Program
  • Brodalumab is available only through a restricted program under a REMS called the brodalumab REMS Program because of the observed suicidal ideation and behavior in subjects treated with brodalumab.
  • Notable requirements of the brodalumab REMS Program include the following:
  • Prescribers must be certified with the program.
  • Patients must sign a Patient-Prescriber Agreement Form.
  • Pharmacies must be certified with the program and must only dispense to patients who are authorized to receive brodalumab.
  • Further information, including a list of qualified pharmacies, is available at www.SILIQREMS.com or by calling the brodalumab REMS Program Call Center at 855-511-6135.
Infections
  • Brodalumab may increase the risk of infections. In clinical trials, subjects treated with brodalumab had a higher rate of serious infections than subjects treated with placebo (0.5% versus 0.2%) and higher rates of fungal infections (2.4% versus 0.9%). One case of cryptococcal meningitis occurred in a subject treated with brodalumab during the 12-week randomized treatment period and led to discontinuation of therapy.
  • During the course of clinical trials for plaque psoriasis, the exposure-adjusted rates for infections and serious infections were similar in the subjects treated with brodalumab and those treated with ustekinumab.
  • In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing brodalumab. Instruct patients to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a serious infection or is not responding to standard therapy for the infection, monitor the patient closely and discontinue brodalumab therapy until the infection resolves.
Risk for Latent Tuberculosis Reactivation
  • Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with brodalumab. Do not administer brodalumab to patients with active TB infection. Initiate treatment for latent TB prior to administering brodalumab.
  • Consider anti-TB therapy prior to initiation of brodalumab in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Closely monitor patients receiving brodalumab for signs and symptoms of active TB during and after treatment.
Crohn’s Disease
  • In psoriasis trials, which excluded subjects with active Crohn’s disease, Crohn’s disease occurred in one subject during treatment with brodalumab and led to discontinuation of therapy. In other trials, exacerbation of Crohn’s disease was observed with brodalumab use.
  • Brodalumab is contraindicated in patients with Crohn’s disease.
  • Discontinue brodalumab if the patient develops Crohn’s disease while taking brodalumab.
Immunizations
  • Avoid use of live vaccines in patients treated with brodalumab. No data are available on the ability of live or inactive vaccines to elicit an immune response in patients being treated with brodalumab.

Adverse Reactions

Clinical Trials Experience

  • Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
  • The overall safety population included 4558 subjects (3066 brodalumab, 613 ustekinumab, 879 placebo) in controlled clinical trials and open-label extension studies. The majority of subjects were male (69%), white (91%), and aged 40-64 years old (58%). One-third of subjects reported previous biologic use prior to enrollment. Across the clinical development program, 4464 subjects received at least one dose of brodalumab; 3755 subjects were exposed to brodalumab for at least 1 year.
Weeks 0 to 12:
  • Data from one multicenter, randomized, placebo-controlled trial (Trial 1), two multicenter, randomized, placebo- and active-controlled trials (Trials 2 and 3), and one dose-finding trial (Trial 4) in plaque psoriasis were pooled to evaluate the safety of brodalumab (210 mg weekly at Weeks 0, 1, and 2, followed by treatments every 2 weeks [Q2W]) compared to placebo for up to 12 weeks after treatment initiation.
  • During the 12-week, randomized treatment period, about 1% of the subjects in the treatment groups (brodalumab, ustekinumab and placebo) discontinued treatment because of adverse events. Adverse events leading to discontinuation of brodalumab included neutropenia, arthralgia, and urticaria. The proportion of subjects who developed serious adverse events was similar among the brodalumab, ustekinumab, and placebo groups.
  • TABLE 1 summarizes the adverse reactions that occurred at a rate of at least 1% and at a higher rate in the brodalumab 210 mg Q2W group than in the placebo group during the 12-week randomized treatment period of the pooled trials.
This image is provided by the National Library of Medicine.
  • Adverse reactions that occurred in less than 1% of subjects in the brodalumab group through Week 12 were conjunctivitis and candida infections (including oral [0.2%], genital [0.1%], and esophageal [0.1%] versus none in the placebo group).
Week 0 to End of Trial:
  • Through Week 52, exposure-adjusted rates of serious adverse events were similar between subjects treated with brodalumab and those treated with ustekinumab. Through the end of the trial, the exposure-adjusted rates of treatment-emergent serious adverse events were similar to those seen in the 52-week period in the subjects treated with brodalumab.
Specific Adverse Reactions:

Suicidal Ideation and Behavior

  • During the 12-week randomized treatment period in the pooled trials, one subject in the brodalumab group attempted suicide and none in the placebo or ustekinumab groups. From initiation through Week 52 of the trials, suicidal ideation or behavior occurred in 7 of 4019 subjects (0.2 per 100 subject-years) treated with brodalumab and in 2 of 613 subjects (0.4 per 100 subject-years) treated with ustekinumab.
  • During the course of the clinical trials for plaque psoriasis, suicidal ideation or behavior occurred in 34 of 4464 subjects treated with brodalumab (0.37 per 100 subject-years). Eight of the 10 subjects who attempted or completed suicide had a history of depression and/or suicidal ideation or behavior.

Infections

  • During the 12-week randomized treatment period, infections occurred in 25.4% of the brodalumab group compared to 23.4% of the placebo group. The majority of infections consisted of nasopharyngitis, upper respiratory tract infection, pharyngitis, urinary tract infections, bronchitis, and influenza, and did not necessitate treatment discontinuation. The brodalumab group had a higher rate of fungal infections compared to the placebo group (1.8% vs 0.9%). The fungal infections were primarily non-serious skin and mucosal candida infections.

Neutropenia

  • During the 12-week randomized treatment period, neutropenia occurred in 0.7% of subjects in the brodalumab group. Most adverse reactions of neutropenia were transient. In subjects with normal absolute neutrophil count (ANC) at baseline, a reduction in ANC occurred in 6.8% of subjects in the brodalumab group, compared to 3.3% in the ustekinumab group, and 3.6% in the placebo group. Neutropenia ≥ Grade 3 (< 1000/mm3) occurred in 0.5% of subjects in the brodalumab group compared to 0.2% of subjects in the ustekinumab group and none in the placebo group. From Week 0 to end of trial, the exposure-adjusted rate of treatment-emergent neutropenia was 0.4 per 100 subject-years (0.1 per 100 subject-years were ≥ Grade 3). No serious infections were associated with cases of neutropenia.

Immunogenicity

  • As with all therapeutic proteins, there is potential for immunogenicity with brodalumab. Approximately 3% of subjects treated with brodalumab developed antibodies to brodalumab through the 52-week treatment period. Of the subjects who developed antibodies to brodalumab, none had antibodies that were classified as neutralizing. However, the assay to test for neutralizing antibodies had limitations detecting neutralizing antibodies in the presence of brodalumab; therefore, the incidence of neutralizing antibody development could be underestimated.
  • The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to brodalumab with the incidence of antibodies to other products may be misleading.

Postmarketing Experience

There is limited information regarding Brodalumab Postmarketing Experience in the drug label.

Drug Interactions

  • Live Vaccinations
  • CYP450 Substrates
Live Vaccinations
  • Avoid use of live vaccines in patients treated with brodalumab.
CYP450 Substrates
  • The formation of CYP450 enzymes can be altered by increased levels of certain cytokines (e.g., IL-1, IL-6, IL-10, TNFα, IFN) during chronic inflammation. Treatment with brodalumab may modulate serum levels of some cytokines.
  • Therefore, upon initiation or discontinuation of brodalumab in patients who are receiving concomitant drugs which are CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for effect (e.g., for warfarin) or drug concentration (e.g., for cyclosporine) and consider dosage modification of the CYP450 substrate.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA):

Risk Summary
  • There are no human data on brodalumab use in pregnant women to inform a drug associated risk. Human IgG antibodies are known to cross the placental barrier; therefore, brodalumab may be transmitted from the mother to the developing fetus. In a combined embryofetal development and pre- and post-natal development study, no adverse developmental effects were observed in infants born to pregnant monkeys after subcutaneous administration of brodalumab during organogenesis through parturition at doses up to 26 times the maximum recommended human dose (MRHD).
  • The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
Data (Animal)
  • A combined embryofetal development and pre- and post-natal development study was conducted in cynomolgus monkeys administered brodalumab. No brodalumab-related effects on embryofetal toxicity or malformations, or on morphological, functional or immunological development were observed in infants from pregnant monkeys administered weekly subcutaneous doses of brodalumab up to 26 times the MRHD from the beginning of organogenesis to parturition (on a mg/kg basis of 90 mg/kg/week).


Pregnancy Category (AUS): There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Brodalumab in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Brodalumab during labor and delivery.

Nursing Mothers

Risk Summary
  • There are no data on the presence of brodalumab in human milk, the effects on the breastfed infant, or the effects on milk production. Brodalumab was detected in the milk of lactating cynomolgus monkeys. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for brodalumab and any potential adverse effects on the breastfed infant from brodalumab or from the underlying maternal condition.

Pediatric Use

  • The safety and effectiveness of brodalumab have not been evaluated in pediatric patients.

Geriatic Use

  • Of the 3066 plaque psoriasis subjects initially randomized to brodalumab in clinical trials, 192 (6%) were ≥ 65 years old and no subjects were ≥ 75 years old. Although no differences in safety or efficacy were observed between older and younger subjects, the number of subjects aged 65 years and older was not sufficient to determine whether they responded differently from younger subjects.

Gender

There is no FDA guidance on the use of Brodalumab with respect to specific gender populations.

Race

There is no FDA guidance on the use of Brodalumab with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Brodalumab in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Brodalumab in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Brodalumab in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Brodalumab in patients who are immunocompromised.

Administration and Monitoring

Administration

Tuberculosis Assessment Prior to Initiation of Brodalumab
  • Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with brodalumab.
Important Administration Instructions
  • Administer brodalumab subcutaneously. Each prefilled syringe is for single-dose only.
  • Instruct patients to review the Medication Guide before use. Brodalumab is intended for use under the guidance and supervision of a healthcare professional. Patients may self-inject brodalumab when deemed appropriate by a healthcare professional and after proper training in subcutaneous injection technique using the prefilled syringe.
  • Advise patients who are self-administering to inject the full dose and to read the Instructions for Use before administration (see Instructions for Use).
  • Do not inject brodalumab into areas where the skin is tender, bruised, red, hard, thick, scaly, or affected by psoriasis.
Preparation of Brodalumab Prefilled Syringe
  • Allow brodalumab prefilled syringe to reach room temperature (approximately 30 minutes) before injecting. Do not warm in any other way. Do not remove the gray needle cap on the prefilled syringe while allowing it to reach room temperature.
  • Visually inspect brodalumab for particles and discoloration prior to administration. brodalumab is a clear to slightly opalescent, colorless to slightly yellow solution. A few translucent to white, amorphous proteinaceous particles may be present. Do not use brodalumab if it is cloudy or discolored or if foreign matter is present.
  • Instruct patients to use the prefilled syringe and to inject the full amount (1.5 mL), which provides 210 mg of brodalumab, according to the directions provided in the Instructions for Use.

Monitoring

  • Reductions in the fraction of body surface area affected, the nature and severity of psoriatic induration, erythema, and scaling are indicative of efficacy.
  • TB; prior to and during therapy.
  • Manifestations of suicidal ideation and behavior, new onset or worsening depression, anxiety, or other mood changes.

IV Compatibility

There is limited information regarding the compatibility of Brodalumab and IV administrations.

Overdosage

There is limited information regarding Brodalumab overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.

Pharmacology

Brodalumab?
Therapeutic monoclonal antibody
Source u
Target Interleukin 17 receptor A
Identifiers
CAS number 1174395-19-7
ATC code L04AC12
PubChem ?
Chemical data
Formula C6372H9840N1712O1988S52 
Mol. mass 144.06 kg/mol
Synonyms KHK4827, AMG 827
Pharmacokinetic data
Bioavailability ?
Metabolism ?
Half life ?
Excretion ?
Therapeutic considerations
Pregnancy cat.

?

Legal status

Prescription only

Routes ?

Mechanism of Action

  • Brodalumab is a human monoclonal IgG2 antibody that selectively binds to human IL-17RA and inhibits its interactions with cytokines IL-17A, IL-17F, IL-17C, IL-17A/F heterodimer and IL-25. IL-17RA is a protein expressed on the cell surface and is a required component of receptor complexes utilized by multiple IL-17 family cytokines. Blocking IL-17RA inhibits IL-17 cytokine-induced responses including the release of pro-inflammatory cytokines and chemokines.

Structure

There is limited information regarding Brodalumab Structure in the drug label.

Pharmacodynamics

  • Elevated levels of IL-17A, IL-17C and IL-17F are found in psoriatic plaques. Serum IL-17A levels, measured at Weeks 12, 24, and 48 of brodalumab 210 mg every 2 weeks of treatment, were higher than the baseline levels in subjects with moderate to severe plaque psoriasis. The relationship between the pharmacodynamic activity and the mechanism(s) by which brodalumab exerts its clinical effects is unknown.

Pharmacokinetics

Absorption
  • Following a single subcutaneous dose of 210 mg in subjects with plaque psoriasis, brodalumab reached peak mean (±SD) serum concentration (Cmax) of 13.4±7.3 mcg/mL by approximately 3 days post dose. The mean (±SD) area-under-the-concentration-time curve (AUC) of brodalumab was 111±64 mcg•day/mL.
  • Following multiple subcutaneous doses of 210 mg every 2 weeks, steady-state was achieved by Week 4. The mean (±SD) Cmax was 20.6±14.6 mcg/mL and the mean (±SD) AUC over the two week dosing interval was 227±167 mcg•day/mL.
  • Following subcutaneous administration, brodalumab bioavailability was approximately 55%.
Distribution
  • Following a single subcutaneous administration of brodalumab 210 mg in subjects with plaque psoriasis, the mean (±SD) apparent volume of distribution (Vz/F) of brodalumab was 8.9±9.4 L.
Elimination
  • The metabolic pathway of brodalumab has not been characterized. As a human monoclonal IgG2 antibody, brodalumab is expected to be degraded into small peptides and amino acids via catabolic pathways in a manner similar to endogenous IgG.
  • Following a single subcutaneous administration of brodalumab 210 mg in subjects with plaque psoriasis, the mean (±SD) apparent total clearance (CL/F) was 3.0±3.5 L/day. The clearance of brodalumab increased with decreasing doses due to nonlinear elimination.
Dose Linearity
  • Brodalumab exhibited non-linear pharmacokinetics with exposures that increased greater than dose-proportionally over a dose range from 140 mg (approximately 0.67 times the recommended dose) to 350 mg (approximately 1.67 times the recommended dose) following subcutaneous administrations in subjects with plaque psoriasis.
Weight
  • Brodalumab trough concentrations were lower in subjects with higher body weight.
Specific Populations

Hepatic or Renal Impairment

  • No trials were conducted to assess the effect of hepatic or renal impairment on the pharmacokinetics of brodalumab.

Age: Geriatric Population

  • Population pharmacokinetic analysis indicated that age did not significantly influence the clearance of brodalumab in subjects with plaque psoriasis. Subjects who were 65 years or older had a similar brodalumab clearance as compared to subjects less than 65 years old.
Drug Interaction Studies
  • In subjects with plaque psoriasis, one week following a single subcutaneous administration of 210 mg brodalumab, the exposure of midazolam (CYP3A4 substrate) was increased by 24%.

Nonclinical Toxicology

Carcinogenesis, Mutagenesis, Impairment of Fertility
  • Animal studies have not been conducted to evaluate the carcinogenic or mutagenic potential of brodalumab. The published literature is mixed on the potential effects on malignancy risk due to the inhibition of the IL-17RA, the pharmacological action of brodalumab. Some published literature suggests that IL-17A directly promotes cancer cell invasion, which suggests a potential beneficial effect of brodalumab. However, other reports indicate IL-17A promotes T-cell mediated tumor rejection, which suggests a potential adverse effect by brodalumab. However, inhibition of the IL-17RA with brodalumab has not been studied in these models. Therefore, the relevance of experimental findings in these models for malignancy risk in humans is unknown.
  • In cynomolgus monkeys, there were no effects on fertility parameters such as changes in reproductive organs or sperm analysis following subcutaneous administration of brodalumab at dose levels up to 90 mg/kg/week for six months (26 times the MRHD on a mg/kg basis). The monkeys were not mated in this study to evaluate effects on fertility.

Clinical Studies

  • Three multicenter, randomized, double-blind, controlled trials (Trials 1, 2, and 3) enrolled a total of 4373 subjects 18 years of age and older with at least a 6-month history of moderate to severe plaque psoriasis, defined as having a minimum affected body surface area (BSA) of 10%, a Psoriasis Area and Severity Index (PASI) score ≥ 12, a static Physician’s Global Assessment (sPGA) score ≥3 in the overall assessment (plaque thickness/induration, erythema, and scaling) of psoriasis on a severity scale of 0 to 5, and who were candidates for systemic therapy or phototherapy. In all three trials, subjects were randomized to subcutaneous treatment with placebo or brodalumab 210 mg at Weeks 0, 1, and 2, followed by treatments every 2 weeks [Q2W] through Week 12. In the two active comparator trials (Trials 2 and 3), subjects randomized to ustekinumab received a 45 mg dose if their weight was less than or equal to 100 kg and a 90 mg dose if their weight was greater than 100 kg at Weeks 0, 4, and 16, followed by the same dose every 12 weeks.
  • All three trials assessed the change from baseline to Week 12 compared to placebo in the two co-primary endpoints: 1) PASI 75, the proportion of subjects who achieved at least a 75% reduction in the PASI composite score that takes into consideration both the percentage of body surface area affected and the nature and severity of psoriatic changes (induration, erythema, and scaling) within the affected region, and 2) the proportion of subjects with an sPGA of 0 (clear) or 1 (almost clear), and at least a 2-point improvement from baseline. In Trials 2 and 3, comparisons were also made to ustekinumab for the primary endpoint of the proportion of subjects who achieved a reduction in PASI score of 100% (PASI 100) from baseline at Week 12.
  • Other evaluated outcomes included the proportion of subjects who achieved an sPGA of 0 (clear) at Week 12, and the proportion of subjects who achieved a Psoriasis Symptom Inventory (PSI) score of 0 (not at all) or 1 (mild) on every item (itch, redness, scaling, burning, stinging, cracking, flaking, and pain) at Week 12. Baseline demographics and disease characteristics were generally consistent across all treatment groups in all three trials. Subjects were predominantly men (69%) and white (91%), with a mean age of 45 years. The mean baseline body weight was 90.5 kg and 28% of subjects had body weight greater than 100 kg. The baseline PASI score ranged from 9.4 to 72 (median: 17.4) and the baseline affected BSA ranged from 10 to 97% (median: 21%). Baseline sPGA scores ranged from “3 (moderate)” (58%) to “5 (very severe)” (5%).
  • Approximately 21% of subjects had a history of psoriatic arthritis. Approximately 30% of subjects had previously received a biologic therapy and 12% of subjects had failed previous biologic therapy.
Clinical Response at Week 12
  • The results of Trials 1, 2, and 3 are presented in TABLE 2.
This image is provided by the National Library of Medicine.
  • Examination of age, gender, race, use of prior systemic or phototherapy, and use of prior biologics did not identify differences in response to brodalumab among these subgroups.
  • At Week 12, compared to subjects in the placebo group, a greater proportion of subjects in brodalumab 210 mg Q2W group achieved a Psoriasis Symptom Inventory (PSI) score of 0 (not at all) or 1 (mild) on every item (itch, redness, scaling, burning, stinging, cracking, flaking, pain).
Maintenance of Effect
  • In Trial 1, subjects randomized to receive brodalumab and who were responders at Week 12 (i.e., sPGA of 0 or 1) were re-randomized to receive either placebo or brodalumab. Among responders at Week 12, 83% (69/83) of subjects re-randomized to continued treatment with brodalumab 210 mg Q2W maintained this response (sPGA of 0 or 1) at Week 52 compared to none (0/84) who were re-randomized to placebo and withdrawn from brodalumab. In addition, 87% (72/83) of subjects re-randomized to continued treatment with brodalumab 210 mg Q2W achieved PASI 75 response at Week 52 compared to none (0/84) who were re-randomized to placebo and withdrawn from brodalumab.
  • Trials 2 and 3 included a re-randomized phase during which subjects originally randomized to receive brodalumab during the first 12 weeks were re-randomized to one of four brodalumab regimens at the Week 12 visit and placebo subjects were crossed over to receive brodalumab 210 mg Q2W. Subjects receiving ustekinumab continued the same treatment until crossed over at Week 52 to brodalumab 210 mg Q2W. For sPGA 0 or 1 responders at Week 12, the percentage of subjects who maintained this response at Week 52 was 79% for subjects treated with brodalumab 210 mg Q2W. For PASI 100 responders at Week 12, 72% of the subjects who continued on brodalumab 210 mg Q2W maintained the response at Week 52.

How Supplied

  • Brodalumab (brodalumab) Injection is available in a single-dose prefilled syringe containing a sterile, preservative-free clear to slightly opalescent, colorless to slightly yellow solution that may contain a few translucent to white, amorphous particles.
  • NDC 0187-0004-02: Carton of two 210 mg/1.5 mL single-dose prefilled syringes.

Storage

  • Store refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light and physical damage during storage.
  • When necessary, prefilled syringes can be stored at room temperature up to a maximum of 77°F (25°C) in the original carton for a maximum single period of 14 days with protection from light and sources of heat. Once the prefilled syringe has reached room temperature, do not place back into the refrigerator. Discard after 14 days at room temperature.
  • Do not freeze.
  • Do not shake.

Images

Drug Images

Package and Label Display Panel

This image is provided by the National Library of Medicine.

Patient Counseling Information

Suicidal Thoughts and Behavior
  • Instruct patients and their caregivers to monitor for the emergence of suicidal thoughts and behavior and promptly seek medical attention if the patient experiences suicidal thoughts, new or worsening depression, anxiety, or other mood changes.
  • Instruct patients to carry the wallet card provided and to call the National Suicide Prevention Lifeline at 1-800-273-8255 if they experience suicidal thoughts.
Brodalumab REMS Program
  • Because of the observed suicidal thoughts and behavior in subjects treated with brodalumab, brodalumab is available only through a restricted program called the brodalumab REMS Program. Inform the patient of the following:
  • Patients must enroll in the program.
  • Patients will be given a brodalumab Patient Wallet Card that they should carry with them at all times. This card describes symptoms which, if experienced, should prompt the patient to immediately seek medical evaluation. Advise the patient to show the brodalumab Patient Wallet Card to other treating healthcare providers.
  • Brodalumab is available only from certified pharmacies participating in the program. Therefore, provide patients with the telephone number and website for information on how to obtain the product.
Infections
  • Inform patients that brodalumab may lower the ability of their immune system to fight infections. Instruct patients of the importance of communicating any history of infections to their healthcare providers and to contact their healthcare providers if they develop any signs or symptoms of infection.
Crohn’s Disease
  • Instruct patients to seek medical advice if they develop signs and symptoms of Crohn’s disease.
Instructions for Injection
  • Instruct the patient to perform the first self-injection under the guidance and supervision of a qualified healthcare professional for proper training in subcutaneous injection technique.
  • Instruct patients who are self-administering to inject the full dose of brodalumab.
  • Instruct patients or caregivers in the technique of proper syringe and needle disposal.

Precautions with Alcohol

Alcohol-Brodalumab interaction has not been established. Talk to your doctor regarding the effects of taking alcohol with this medication.

Brand Names

  • Siliq

Look-Alike Drug Names

There is limited information regarding Brodalumab Look-Alike Drug Names in the drug label.

Drug Shortage Status

Drug Shortage

Price

References

The contents of this FDA label are provided by the National Library of Medicine.


Linked-in.jpg